The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure
Open accessAbstract
The current study assesses the antihypertensive efficacy and safety of the investigational angiotensin receptor blocker (ARB), azilsartan medoxomil (AZL‐M), compared with placebo and the ARB olmesartan medoxomil (OLM‐M). This randomized, double‐blind, placebo‐controlled, multicenter study assessed change from baseline in mean 24‐hour ambulatory systolic blood pressure (SBP) following 6 weeks of treatment. Patients with primary hypertension ( n =1275) and baseline 24‐hour mean ambulatory systolic pressure ≥130 mm Hg and ≤170 mm Hg were studied; 142 received placebo and the remainder received 20 mg, 40 mg, or 80 mg AZL‐M or 40 mg OLM‐M. Mean age of participants was 58±11 years, baseline mean 24‐hour SBP was 146 mm Hg. Dose‐dependent reductions in 24‐hour mean SBP at study end occurred in all AZL‐M groups. Reduction in 24‐hour mean SBP was greater with AZL‐M 80 mg than OLM‐M 40 mg by 2.1 mm Hg (95% confidence interval, −4.0 to −0.1; P=.038), while AZL‐M 40 mg was noninferior to OLM‐M 40 mg. The side effect profiles of both ARBs were similar to placebo. AZL‐M is well tolerated and more efficacious at its maximal dose than the highest dose of OLM‐M. J Clin Hypertens (Greenwich). 2011;13:81–88. © 2011 Wiley Periodicals, Inc.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
24-hour ABPM studies demonstrate that azilsartan medoximil provides on average an additional 4 to 8 mm Hg further SBP reduction over other ARBs (eg, valsartan and olmesartan) or the ACE inhibitor ramipril.
“Specifically, 24-hour ABPM studies demonstrate that azilsartan medoximil provides on average an additional 4 to 8 mm Hg further SBP reduction over other ARBs (eg, valsartan and olmesartan) or the ACE inhibitor ramipril.381–383”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [382]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782 · see citing works
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · see citing works
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333 · see citing works
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · see citing works
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700 · see citing works
HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION
Tarver, T. (2014) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,595 · see citing works
US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008
Egan, B. M. (2010) · JAMA · doi:10.1001/jama.2010.650 · Cited by 2,197 · see citing works
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,885 · see citing works
Pitt, B., Segal, R., Martínez, F. A., Meurers, G., Cowley, A. J., Thomas, I., DEEDWANIA, P. C., Ney, D. E., Snavely, D. B., & Chang, P. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01187-2 · Cited by 1,656 · see citing works
Blood Pressure Lowering Treatment Trialists’ Collaboration (2008) · BMJ · doi:10.1136/bmj.39548.738368.be · Cited by 739 · see citing works
Poggio, E. D., Wang, X., Greene, T., Lente, F. V., & Hall, P. M. (2004) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004060447 · Cited by 643 · see citing works
Cardiovascular prevention and blood pressure reduction
Staessen, J. A., Wang, J., & Thijs, L. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00002 · Cited by 482 · see citing works
Oparil, S., Williams, D., Chrysant, S. G., Marbury, T. C., & Neutel, J. (2001) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2001.01136.x · Cited by 264 · see citing works
Divergent Results Using Clinic and Ambulatory Blood Pressures
Bakris, G. L., Lindholm, L. H., Black, H. R., Krum, H., Linas, S. L., Linseman, J. V., Arterburn, S., Sager, P. T., & Weber, M. A. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.156976 · Cited by 197 · see citing works
Self-citationTrends in obesity and abdominal obesity among adults in the United States from 1999–2008
Ford, E. S., Li, C., Zhao, G., & Tsai, J. H. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.186 · Cited by 169 · see citing works
McMurray, J. J. V., Solomon, S. D., Pieper, K. S., Reed, S. D., Rouleau, J. L., Velazquez, E. J., White, H. D., Howlett, J. G., Swedberg, K. B., Maggioni, A. P., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.055 · Cited by 161 · see citing works
Ojima, M., Igata, H., Tanaka, M., Sakamoto, H., Kuroita, T., Kohara, Y., Kubo, K., Fuse, H., Imura, Y., Kusumoto, K., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176636 · Cited by 151 · see citing works
Elliott, W. J., Plauschinat, C. A., Skrepnek, G. H., & Gause, D. (2007) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2007.01.060094 · Cited by 130 · see citing works
Dolan, E., Stanton, A. V., Thom, S., Caulfield, M. J., Atkins, N., McInnes, G. T., Collier, D., Dicker, P., & O'Brien, E. T. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328322cd62 · Cited by 128 · see citing works
Cruickshank, J. K., Mbanya, J. C., Wilks, R., Balkau, B., Forrester, T., Anderson, S. G., Mennen, L. I., Forhan, A., Riste, L., & McFarlane‐Anderson, N. (2001) · Journal of Hypertension · doi:10.1097/00004872-200101000-00006 · Cited by 120 · see citing works
Stolarz‐Skrzypek, K., Thijs, L., Richart, T., Li, Y., Hansen, T. W., Boggia, J. G., Kuznetsova, T., Kikuya, M., Kawecka−Jaszcz, K., & Staessen, J. A. (2010) · Hypertension Research · doi:10.1038/hr.2010.110 · Cited by 96 · see citing works
Fagard, R. H., Thijs, L., Staessen, J. A., Clement, D. L., Buyzere, M. D., & Bacquer, D. D. (2008) · Blood Pressure Monitoring · doi:10.1097/mbp.0b013e32831054f5 · Cited by 66 · see citing works
Püchler, K., Laeis, P., & Stumpe, K. O. (2001) · Journal of Hypertension · doi:10.1097/00004872-200106001-00006 · Cited by 59 · see citing works
Zannad, F. M., & Fay, R. (2007) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00464.x · Cited by 35 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153 · see citing works
Self-citationThe past, present and future of renin–angiotensin aldosterone system inhibition
Mentz, R. J., Bakris, G. L., Waeber, B., McMurray, J. J. V., Gheorghiade, M., Ruilope, L. M., Maggioni, A. P., Swedberg, K. B., Piña, I. L., Fiuzat, M., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.007 · Cited by 117 · see citing works
Self-citationSica, D. A., White, W. B., Weber, M. A., Bakris, G. L., Pérez, A., Cao, C., Handley, A., & Kupfer, S. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00482.x · Cited by 117 · see citing works
Self-citationRakugi, H., Enya, K., Sugiura, K., & Ikeda, Y. (2012) · Hypertension Research · doi:10.1038/hr.2012.8 · Cited by 114 · see citing works
Angiotensin Receptor Blockers: Pharmacology, Efficacy, and Safety
Taylor, A. A., Siragy, H. M., & Nesbitt, S. D. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00518.x · Cited by 100 · see citing works
Bakris, G. L., Sica, D., White, W. B., Cushman, W. C., Weber, M. A., Handley, A., Song, E., & Kupfer, S. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.05.023 · Cited by 90 · see citing works
Self-citationAhmadian, E., Khosroushahi, A. Y., Eftekhari, A., Farajnia, S., Babaei, H., & Eghbal, M. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.117 · Cited by 84 · see citing works
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
Kurtz, T. W., Kajiya, & Kurtz (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s22595 · Cited by 76 · see citing works
Ghazi, L., & Drawz, P. E. (2017) · F1000Research · doi:10.12688/f1000research.9692.1 · Cited by 71 · see citing works
Azilsartan Medoxomil: A New Angiotensin II Receptor Antagonist for Treatment of Hypertension
Baker, W. L., & White, W. B. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q468 · Cited by 70 · see citing works
Self-citationCushman, W. C., Bakris, G. L., White, W. B., Weber, M. A., Sica, D. A., Roberts, A., Lloyd, E., & Kupfer, S. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.188284 · Cited by 68 · see citing works
Self-citationAzilsartan Medoxomil: A New Angiotensin Receptor Blocker
Zaiken, K., & Cheng, J. W. M. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.007 · Cited by 66 · see citing works
Molecular and cellular effects of azilsartan
Kajiya, T., Ho, C. I., Wang, J., Vilardi, R. F., & Kurtz, T. W. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834c46fd · Cited by 64 · see citing works
Bönner, G., Bakris, G. L., Sica, D., Weber, M. A., White, W. B., Perez, A., Cao, C., Handley, A., & Kupfer, S. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.6 · Cited by 61 · see citing works
Self-citationMiura, S.-I., Okabe, A., Matsuo, Y., Karnik, S. S., & Saku, K. (2012) · Hypertension Research · doi:10.1038/hr.2012.147 · Cited by 60 · see citing works
Key advances in antihypertensive treatment
Paulis, L., Steckelings, U. M., & Unger, T. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.33 · Cited by 53 · see citing works
Perry, C. M. (2012) · Clinical Drug Investigation · doi:10.1007/bf03261917 · Cited by 50 · see citing works
Discovery of Inhibitors of Insulin‐Regulated Aminopeptidase as Cognitive Enhancers
Andersson, H., & Hallberg, M. (2012) · International Journal of Hypertension · doi:10.1155/2012/789671 · Cited by 48 · see citing works
Sica, D. A., Bakris, G. L., White, W. B., Weber, M. A., Cushman, W. C., Huang, P., Roberts, A., & Kupfer, S. (2012) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00616.x · Cited by 46 · see citing works
Self-citationSueta, D., Kataoka, K., Koibuchi, N., Toyama, K., Uekawa, K., Katayama, T., Ma, M., Nakagawa, T., Waki, H., Maeda, M., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000035 · Cited by 37 · see citing works
White, W. B., Cuadra, R. H., Lloyd, E., Bakris, G. L., & Kupfer, S. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000839 · Cited by 35 · see citing works
Self-citationBronson, J. J., Dhar, T. G. M., Ewing, W. R., & Lönberg, N. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00031-x · Cited by 33 · see citing works
Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker.
Jones, J. D., Jackson, S., Agboton, C., & Martin, T. S. (2011) · Europe PMC (PubMed Central) · Cited by 33 · see citing works
A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction
for the ALICE (All-Literature Investigation of Cardiovascular Evidence) Group, Takagi, H., Mizuno, Y., Niwa, M., Goto, S.-N., & Umemoto, T. (2013) · Hypertension Research · doi:10.1038/hr.2013.142 · Cited by 32 · see citing works
Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat
Khan, A. H., Neckář, J., Cummens, B., Wahl, G., & Imig, J. D. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6530-0 · Cited by 30 · see citing works
Farsang, C. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s23468 · Cited by 30 · see citing works
Amin, R. R. H., & Aziz, T. A. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s365090 · Cited by 29 · see citing works
Angeloni, E. (2016) · Core evidence · doi:10.2147/ce.s81776 · Cited by 27 · see citing works
Vekariya, P. P., & Joshi, H. S. (2013) · ISRN Spectroscopy · doi:10.1155/2013/572170 · Cited by 26 · see citing works
Azilsartan: Current Evidence and Perspectives in Management of Hypertension
Pradhan, A. K., Tiwari, A., & Sethi, R. (2019) · International Journal of Hypertension · doi:10.1155/2019/1824621 · Cited by 25 · see citing works
for the EARLY Registry Group, Gitt, A. K., Bramlage, P., Potthoff, S. A., Baumgart, P., Mahfoud, F., Buhck, H., Ehmen, M., Ouarrak, T., Senges, J., et al. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0222-6 · Cited by 25 · see citing works
Georgiopoulos, G. A., Katsi, V. K., Oikonomou, D., Vamvakou, G. D., Koutli, E., Laina, A., Tsioufis, C., Nihoyannopoulos, P., & Tousoulis, D. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00235 · Cited by 24 · see citing works
Wang, J., Zhang, M., Feng, Y., Ma, C., Wang, T., Zhu, Z., & Kario, K. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14227 · Cited by 23 · see citing works
Special Article - The management of resistant hypertension: A 2020 update
Carey, R. M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.08.001 · Cited by 22 · see citing works
Critical evaluation of the efficacy and tolerability of azilsartan
Caterina, A. D., Harper, A. R., & Cuculi (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s22589 · Cited by 22 · see citing works
Angeli, F., Verdecchia, P., Pascucci, C., Poltronieri, C., & Reboldi, G. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.769521 · Cited by 22 · see citing works
Lam, S. (2011) · Cardiology in Review · doi:10.1097/crd.0b013e31822e9ba3 · Cited by 22 · see citing works
Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension
Hjermitslev, M. H., Grimm, D. G., Wehland, M., Simonsen, U., & Krüger, M. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12800 · Cited by 22 · see citing works
Azilsartan/chlorthalidone combination therapy for blood pressure control
Cheng, J. W. M. (2013) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s34792 · Cited by 17 · see citing works
Bakris, G. L., Zhao, L., Kupfer, S., Juhász, A., Hisada, M., Lloyd, E., & Oparil, S. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13230 · Cited by 16 · see citing works
Self-citationEffects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension
Weber, M. A., White, W. B., Sica, D. A., Bakris, G. L., Cao, C., Roberts, A., & Kupfer, S. (2014) · Blood Pressure Monitoring · doi:10.1097/mbp.0000000000000027 · Cited by 17 · see citing works
Self-citationShiga, Y., Miura, S., Motozato, K., Norimatsu, K., Yano, M., Hitaka, Y., Adachi, S., Kuwano, T., Inoue, K., Inoue, A., et al. (2017) · International Heart Journal · doi:10.1536/ihj.16-285 · Cited by 17 · see citing works
Kourlaba, G., Gialama, F., Tsioufis, K., & Maniadakis, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.115 · Cited by 16 · see citing works
Preston, R. A., Karim, A., Dudkowski, C., Zhao, Z., Garg, D. C., Lenz, O., & Sica, D. A. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0044-y · Cited by 14 · see citing works
Self-citationOut-of-office blood pressure: from measurement to control
Baguet, J.-P. (2012) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s30409 · Cited by 14 · see citing works
Pérez, A., & Cao, C. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12873 · Cited by 14 · see citing works
Self-citationSezai, A., Osaka, S., Yaoita, H., Arimoto, M., Hata, H., Shiono, M., & Sakino, H. (2016) · Annals of Thoracic and Cardiovascular Surgery · doi:10.5761/atcs.oa.16-00054 · Cited by 13 · see citing works
Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases
Balakumar, P., & Jagadeesh, G. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_36 · Cited by 12 · see citing works
Nie, Y.-Y., Da, Y., Zheng, H., Yang, X., Jia, L., Wen, C.-H., Liang, L.-S., Tian, J., & Chen, Z. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.02.003 · Cited by 12 · see citing works
Miura, S.-I., Matsuo, Y., Nakayama, A., Tomita, S., Suematsu, Y., & Saku, K. (2013) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320313482170 · Cited by 12 · see citing works
Nedogoda, S. V., Chumachek, E. V., Цома, В. В., Salasyuk, A. S., Smirnova, V. O., & Popova, E. A. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-1-70-79 · Cited by 12 · see citing works
Gong, C., Wang, J., Sun, Y. H., Ding, D., Zhong, L., Zhu, M., Sun, J., & Zhang, X. (2014) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.10.004 · Cited by 11 · see citing works
Harrell, R. E., Karim, A., Zhang, W., & Dudkowski, C. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0333-8 · Cited by 11 · see citing works
Cushman, W. C., Bakris, G. L., White, W. B., Weber, M. A., Sica, D. A., Roberts, A., Lloyd, E., & Kupfer, S. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001647 · Cited by 11 · see citing works
Self-citationfor the EARLY Registry Group, Gitt, A. K., Baumgart, P., Bramlage, P., Mahfoud, F., Potthoff, S. A., Senges, J., Schneider, S., Buhck, H., & Schmieder, R. E. (2013) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-13-46 · Cited by 10 · see citing works
Should Two-Drug Initial Therapy for Hypertension Be Recommended for All Patients?
Cowart, J. B., & Taylor, A. A. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0280-9 · Cited by 10 · see citing works
Handley, A., Lloyd, E., Roberts, A., & Barger, B. (2016) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2015.1081213 · Cited by 10 · see citing works
Self-citationClinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension
Shuster, J. E., Shuster, J. E., & Bleske (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s22583 · Cited by 10 · see citing works
Kher, M. N., Bhatt, V. D., Jani, A., & Sheth, N. R. (2020) · Analytical Chemistry Letters · doi:10.1080/22297928.2020.1784788 · Cited by 9 · see citing works
In Vitro Drug Repurposing: Focus on Vasodilators
Ribeiro, E., Costa, B., Vasques‐Nóvoa, F., & Vale, N. (2023) · Cells · doi:10.3390/cells12040671 · Cited by 9 · see citing works
Lanier, G. M., Sankholkar, K., & Aronow, W. S. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31824a0ed7 · Cited by 9 · see citing works
Juhász, A., Wu, J., Hisada, M., Tsukada, T., & Jeong, M. H. (2018) · Clinical Hypertension · doi:10.1186/s40885-018-0086-4 · Cited by 9 · see citing works
Wu, J., Du, X., Lv, Q., Li, Z., Zheng, Z., Xia, Y., Tang, C., Yao, Z., Zhang, J., Long, M., et al. (2020) · Medicine · doi:10.1097/md.0000000000021465 · Cited by 9 · see citing works
Possible benefits of azilsartan compared with other angiotensin II type 1 receptor blockers
Miura, S.-I., & Saku, K. (2014) · Hypertension Research · doi:10.1038/hr.2014.118 · Cited by 8 · see citing works
Pérez, A., & Cao, C. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12895 · Cited by 8 · see citing works
Self-citationPrevention of Coronary Artery Disease: Recent Advances in the Management of Hypertension
Recarti, C., & Unger, T. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0311-2 · Cited by 8 · see citing works
Azilsartan Medoxomil/Chlorthalidone: A New Fixed-Dose Combination Antihypertensive
Pierini, D., & Anderson, K. V. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r618 · Cited by 8 · see citing works
Suehiro, T., Tsuruya, K., Yoshida, H., Tsujikawa, H., Yamada, S., Tanaka, S., Tsuchimoto, A., Eriguchi, M., Fujisaki, K., Torisu, K., et al. (2021) · Kidney & Blood Pressure Research · doi:10.1159/000512365 · Cited by 8 · see citing works
Ferdinand, K. C., Bakris, G. L., Cushman, W. C., Weber, M. A., Lloyd, E., Wu, J., & White, W. B. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.07.022 · Cited by 8 · see citing works
Self-citationAzilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Barrios, V., & Escobar, C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.834887 · Cited by 7 · see citing works
Zhao, D., Liu, H., & Dong, P. (2018) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-018-1859-1 · Cited by 7 · see citing works
Johnson, W. R., White, W. B., Sica, D. A., Bakris, G. L., Weber, M. A., Handley, A., Pérez, A., Cao, C., Kupfer, S., & Saunders, E. (2017) · Journal of Clinical Hypertension · doi:10.1111/jch.12993 · Cited by 7 · see citing works
Self-citationGarg, M., Manik, G., Singhal, A., Singh, V., Varshney, R. K., & Sethi, A. (2020) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_19_19 · Cited by 7 · see citing works
Seo, S. M., Ihm, S., Yi, J., Jeong, S. H., & Kim, B. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14536 · Cited by 7 · see citing works
Kipnes, M. S., Handley, A., Lloyd, E., Barger, B., & Roberts, A. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12474 · Cited by 6 · see citing works
Self-citationKwon, A., & Kim, G.-H. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.05.015 · Cited by 6 · see citing works
An evaluation of the latest evidence relating to renin–angiotensin system inhibitors
Escobar, C., & Barrios, V. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.788149 · Cited by 6 · see citing works
Efficacy of azilsartan medoxomil with chlorthalidone in hypertension
Baker, W. L., Nigro, S. C., & White, W. B. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.924853 · Cited by 6 · see citing works
Self-citationAdachi, S., Miura, S., Shiga, Y., Arimura, T., Kuwano, T., Kitajima, K., Ike, A., Sugihara, M., Iwata, A., Nishikawa, H., et al. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2675w · Cited by 6 · see citing works
Collier, D., Juhász, A., Agabiti‐Rosei, E., Lloyd, E., Hisada, M., Zhao, L., Kupfer, S., & Caulfield, M. J. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13376 · Cited by 6 · see citing works
Self-citationHypertension Therapeutics Update: A Brief Clinical Summary on Azilsartan, Cilnidipine and Nebivolol
Sharma, S. (2015) · Hypertension Journal · doi:10.5005/jp-journals-10043-0019 · Cited by 5 · see citing works
Practical efficacy of olmesartan versus azilsartan in patients with hypertension
Kakio, Y., Uchida, H. A., Umebayashi, R., Takeuchi, H., Okuyama, Y., Hanayama, Y., & Wada, J. (2017) · Blood Pressure Monitoring · doi:10.1097/mbp.0000000000000229 · Cited by 5 · see citing works
Can the effectiveness of hypertension management be improved?
Ruilope, L. M. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.18 · Cited by 5 · see citing works
for the EARLY Registry Group, Bramlage, P., Schmieder, R. E., Gitt, A. K., Baumgart, P., Mahfoud, F., Buhck, H., Ouarrak, T., Ehmen, M., & Potthoff, S. A. (2015) · Trials · doi:10.1186/s13063-015-1100-8 · Cited by 5 · see citing works
A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone
Weber, M. A., Sever, P., Juhász, A., Roberts, A., & Cao, C. (2018) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320318795000 · Cited by 5 · see citing works
Self-citationTamura, K., Ohsawa, M., Kanaoka, T., Maeda, A., Azushima, K., Uneda, K., Wakui, H., Azuma, K., Tsurumi‐Ikeya, Y., & Umemura, S. (2012) · Hypertension Research · doi:10.1038/hr.2012.166 · Cited by 4 · see citing works
Peraman, R., Dakinedi, S. R., Kadiri, R. R., & Malineni, L. (2017) · Journal of Young Pharmacists · doi:10.5530/jyp.2017.9.39 · Cited by 4 · see citing works
Xu, H., Kang, L., Qin, J., Lin, J., Xue, M., & Meng, Z. (2020) · ACS Omega · doi:10.1021/acsomega.0c00156 · Cited by 4 · see citing works
Katsi, V. K., Michalakeas, C. A., Σουλαϊδόπουλος, Σ., Antonopoulos, A. S., Vlachopoulos, C. V., Tousoulis, D., & Tsioufis, K. P. (2021) · Current Hypertension Reviews · doi:10.2174/1573402117666210112144505 · Cited by 4 · see citing works
Deerochanawong, C., Chang, K., Woo, Y. C., Lai, W., & Chutinet, A. (2022) · International Journal of Hypertension · doi:10.1155/2022/2717291 · Cited by 3 · see citing works
Combination Therapy in Hypertension Treatment
Oliva, R., & Bakris, G. L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3694-2_12 · Cited by 3 · see citing works
Self-citationNewer renin–angiotensin–aldosterone system blocker combinations
Lazich, I., & Bakris, G. L. (2011) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283495819 · Cited by 3 · see citing works
Self-citationEfficacy and safety of different doses of azilsartan medoxomil in patients with hypertension
Zhang, Y., Yu, H., Shao, K., Luo, X., Wang, J., & Chen, G. (2019) · Medicine · doi:10.1097/md.0000000000017050 · Cited by 3 · see citing works
Chazova, I. E., & Zhernakova, Y. V. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1844647 · Cited by 3 · see citing works
Khan, Q. A., Sharma, S. S., Mulk, I. U., Li, D., Belay, N. F., Afzal, M., Farrukh, A. M., Asad, M., Baqi, A., & Semakieh, B. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001547 · Cited by 2 · see citing works
Qian, J., Zhang, M., & Chen, Z. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02997-5 · Cited by 2 · see citing works
Hypertension in metabolic syndrome
Kobalava, Z. D., Конради, А. О., & Nedogoda, S. V. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6536 · Cited by 3 · see citing works
Jones, J. D., Jackson, S., & Colquitt, C. (2013) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s34791 · Cited by 2 · see citing works
Тіазиди або тіазидоподібні діуретики в лікуванні артеріальної гіпертензії?
Радченко, Г. Д. (2018) · HYPERTENSION · doi:10.22141/2224-1485.6.56.2017.120323 · Cited by 2 · see citing works
Lee, H., Hong, B., Su, C. T.-T., Bea, S., Jeong, H. E., Jung, K., Cheng, M. C., Chang, Z. C.-J., Lai, E. C., & Lee, J. (2025) · Epidemiology and Health · doi:10.4178/epih.e2025029 · Cited by 2 · see citing works
- Authors
- Bakris, G. L., Sica, D., Weber, M., White, W. B., Roberts, A., Perez, A., Cao, C., & Kupfer, S.
- Affiliations
- University of Connecticut (US)
- State University of New York (US)
- Corresponding author
- Bakris, George L.
- Venue
- The Journal of Clinical Hypertension
- Publisher
- Wiley
- Published
- 2011-01-27
- Volume
- 13
- Issue
- 2
- Pages
- 81-88
- ISSN
- 1524-6175 (ISSN-L)
- 1751-7176
- PMC
- PMC8673073
- OpenAlex
- W2077469844
- Cited by
- 143
- References
- 24
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 13 · 2019: 4 · 2018: 12 · 2017: 9 · 2016: 16 · 2015: 7 · 2014: 5 · 2013: 19 · 2012: 21
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Hypertension (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- PepsiCo
- Gilead Sciences
- FibroGen
- Savient Pharmaceuticals
- Daiichi-Sankyo
- Astellas Pharma
- Servier
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- azilsartan medoxomil, olmesartan medoxomil, angiotensin receptor blockers, antihypertensive efficacy, essential hypertension, 24-hour ambulatory blood pressure, systolic blood pressure, dose-response relationship, drug safety, non-inferiority
- MeSH terms
- Aged, Argentina, Benzimidazoles, Blood Pressure, Blood Pressure Determination, Double-Blind Method, Female, Humans, Hypertension, Imidazoles, Male, Mexico, Middle Aged, Oxadiazoles, Peru, Tetrazoles, United States, Treatment Outcome, Blood Pressure Monitoring, Ambulatory, Racial Groups, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
